Advertisement

AAPS PharmSciTech

, Volume 16, Issue 1, pp 59–66 | Cite as

Serratiopeptidase Loaded Chitosan Nanoparticles by Polyelectrolyte Complexation: In Vitro and In Vivo Evaluation

  • Nitin Mali
  • Preeti Wavikar
  • Pradeep VaviaEmail author
Research Article

Abstract

The aim of the present study was to formulate serratiopeptidase (SER)-loaded chitosan (CS) nanoparticles for oral delivery. SER is a proteolytic enzyme which is very sensitive to change in temperature and pH. SER-loaded CS nanoparticles were fabricated by ionic gelation method using tripolyphosphate (TPP). Nanoparticles were characterized for its particle size, morphology, entrapment efficiency, loading efficiency, percent recovery, and in vitro dissolution study. SER-CS nanoparticles had a particle size in the range of 400–600 nm with polydispersity index below 0.5. SER association was up to 80 ± 4.2%. SER loading and CS/TPP mass ratio were the primary parameters having direct influence on SER-CS nanoparticles. SER-CS nanoparticles were freeze dried using trehalose (20%) as a cryoprotectant. In vitro dissolution showed initial burst followed by sustained release up to 24 h. In vivo anti-inflammatory activity was carried out in rat paw edema model. In vivo anti-inflammatory activity in rat paw edema showed prolonged anti-inflammatory effect up to 32 h relative to plain SER.

KEY WORDS

anti-inflammatory activity chitosan nanoparticle serratiopeptidase TPP 

Notes

Acknowledgments

The authors want to acknowledge DBT and UGC for fellowship and AICTE/NAFETIC and Kusum HealthCare for proving laboratory facilities.

Conflict of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

References

  1. 1.
    des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116(1):1–27.PubMedCrossRefGoogle Scholar
  2. 2.
    Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res. 2007;24(12):2198–206.PubMedCrossRefGoogle Scholar
  3. 3.
    Fd C, Aj T, Dm C, Lq Z, Shi K. Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J Pharm Sci. 2007;96(2):421–7.CrossRefGoogle Scholar
  4. 4.
    Tasset C, Barette N, Thysman S, Ketelslegers J-M, Lemoine D. Polyisobutylcyanoacrylate nanoparticles as sustained release system for calcitonin. J Control Release. 1995;33(1):23–30.CrossRefGoogle Scholar
  5. 5.
    Santander-Ortega MJ, Csaba N, González L, Bastos-González D, Ortega-Vinuesa JL, Alonso MJ. Protein-loaded PLGA-PEO blend nanoparticles: encapsulation, release and degradation characteristics. Colloid Polym Sci. 2010;288(2):141–50.CrossRefGoogle Scholar
  6. 6.
    Lin Y-H, Chang C-H, Wu Y-S, Hsu Y-M, Chiou S-F, Chen Y-J. Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti- < i > Helicobacter pylori</i > therapy. Biomaterials. 2009;30(19):3332–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Santander-Ortega M, Bastos-Gonzalez D, Ortega-Vinuesa J, Alonso M. Insulin-loaded PLGA nanoparticles for oral administration: an in vitro physico-chemical characterization. J Biomed Nanotechnol. 2009;5(1):45–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Patel AR, Kulkarni S, Nandekar TD, Vavia PR. Evaluation of alkyl polyglucoside as an alternative surfactant in the preparation of peptide-loaded nanoparticles. J Microencapsul. 2008;25(8):531–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release. 2004;100(1):5–28.PubMedCrossRefGoogle Scholar
  10. 10.
    Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res. 1989;18(5):379–88.Google Scholar
  11. 11.
    Jadav SP, Patel NH, Shah TG, Gajera MV, Trivedi HR, Shah BK. Comparison of anti-inflammatory activity of serratiopeptidase and diclofenac in albino rats. J Pharmacol Pharmacother. 2010;1(2):116.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Fereidoni M, Ahmadiani A, Semnanian S, Javan M. An accurate and simple method for measurement of paw edema. J Pharmacol Toxicol Methods. 2000;43(1):11–4.PubMedCrossRefGoogle Scholar
  13. 13.
    MAEJIMA K, MIYATA K, TOMODA K. A manganese superoxide dismutase from Serratia marcescens. Agric Biol Chem. 1983;47(7):1537–43.CrossRefGoogle Scholar
  14. 14.
    Rinaudo M. Chitin and chitosan: properties and applications. Prog Polym Sci. 2006;31(7):603–32.CrossRefGoogle Scholar
  15. 15.
    Mao H-Q, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release. 2001;70(3):399–421.PubMedCrossRefGoogle Scholar
  16. 16.
    Tokumitsu H, Ichikawa H, Fukumori Y. Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: preparation by novel emulsion-droplet coalescence technique and characterization. Pharm Res. 1999;16(12):1830–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Mitra S, Gaur U, Ghosh P, Maitra A. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release. 2001;74(1):317–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Calvo P, Remunan-Lopez C, Vila-Jato J, Alonso M. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci. 1997;63(1):125–32.CrossRefGoogle Scholar
  19. 19.
    Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B: Biointerfaces. 2007;59(1):24–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Aktaş Y, Andrieux K, Alonso MJ, Calvo P, Gürsoy RN, Couvreur P, et al. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm. 2005;298(2):378–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115(2):216–25.PubMedCrossRefGoogle Scholar
  22. 22.
    Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeted delivery of small interfering RNA. Int J Pharm. 2010;399(1):1–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan—TPP nanoparticles intended for gene delivery. Colloids Surf B: Biointerfaces. 2005;44(2):65–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Csaba N, Köping-Höggård M, Alonso MJ. Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. Int J Pharm. 2009;382(1):205–14.PubMedCrossRefGoogle Scholar
  25. 25.
    Kumbhar D, Wavikar P, Vavia P. Niosomal Gel of Lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity. AAPS PharmSciTech. 2013;14(3):1072–82.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Crystalline KM, Desoxyribonuclease I. Isolation and general properties spectrophotometric method for the measurement of desoxyribonuclease activity. J Gen Physiol. 1950;33(4):349–62.CrossRefGoogle Scholar
  27. 27.
    Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688–713.PubMedCrossRefGoogle Scholar
  28. 28.
    Date PV, Samad A, Devarajan PV. Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze drying. AAPS PharmSciTech. 2010;11(1):304–13.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2014

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences and TechnologyInstitute of Chemical TechnologyMumbaiIndia
  2. 2.Center for Novel Drug Delivery Systems, Department of Pharmaceutical Sciences and TechnologyInstitute of Chemical TechnologyMumbaiIndia

Personalised recommendations